TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05957926

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hyaluronic acid added to hydroxyapetite
Description: 1. The procedure will be performed under complete aseptic condition, and the surgical field will be swabbed with povidone iodine solution before the operation .~2. Surgical procedure will be performed under local anesthesia (Articaine 4% with 1:100,000 adrenaline ) .~3. A full thickness mucoperiosteal flap will be reflected exposing the area of interest containing the lesion .~4. The pathological lesion will be exposed using rose head bur on low-speed handpiece under copious irrigation by normal saline .~5. The whole pathological tissues will be enucleated and sent for histopathological examination.~6. The cavity will be curetted again to remove any remaining tissues and irrigated with 0.9% normal saline .~7. hydroxyapetite with hyaluronic acid will be inserted in the bony cavity to initiate healing .~8. The flap will be repositioned and sutured with interrupted 3-0 Vicryl suture .

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyapatite alone
Description: 1. The procedure will be performed under complete aseptic condition, and the surgical field will be swabbed with povidone iodine solution before the operation .~2. Surgical procedure will be performed under local anesthesia (Articaine 4% with 1:100,000 adrenaline ) .~3. A full thickness mucoperiosteal flap will be reflected exposing the area of interest containing the lesion .~4. The pathological lesion will be exposed using rose head bur on low-speed handpiece under copious irrigation by normal saline .~5. The whole pathological tissues will be enucleated and sent for histopathological examination.~6. The cavity will be curetted again to remove any remaining tissues and irrigated with 0.9% normal saline .~7. hydroxyapetite will be inserted in the bony cavity to initiate healing .~8. The flap will be repositioned and sutured with interrupted 3-0 Vicryl suture .
Study: NCT05869149

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multilevel restaurant intervention to improve the food environment
Description: FRESH is a restaurant-based intervention in low-income neighborhoods in Baltimore, MD and the Washington, District of Columbia metro area that aims to improve the healthy prepared-food environment for consumers, informed by community members and other stakeholders. FRESH intervention components include food preparation, food access and procurement, and consumer nutrition environment. Activities will take place over 16 months, and include training restaurant chefs to use healthier cooking methods, partnering with restaurant suppliers to offer healthier ingredients, and offering point-of-purchase promotions to educate customers on the healthier promoted food options. Intervention staff will form strong relationships with restaurant owners and chefs via in-person visits at least twice a month. Data from the intervention trial will inform the development of a system dynamics simulation model that will allow stakeholders to test new policy ideas prior to implementation.
Study: NCT06457347

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultra early (<24 hours) ruptured aneurysm clipping
Description: Aneurysms are clipped with open surgery in less than 24 hours after rupture to prevent early rebleeding.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early (24-72 hours) ruptured aneurysm clipping
Description: Aneurysms are clipped with open surgery in 24 to 72 hours after rupture to prevent early rebleeding.
Study: NCT06167915

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30μg dose of LYB002V14
Description: 30μg dose of LYB002V14 vaccine IM, on day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 60μg dose of LYB002V14
Description: 60μg dose of LYB002V14 vaccine IM, on day 0

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo IM, on day 0
Study: NCT05260463

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation
Description: Fractures of the distal fibula are treated with a trauma implant.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation
Description: Fractures of the distal fibula are treated with a trauma implant.
Study: NCT04850495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Given PO
Study: NCT06569706

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nipple-Sparing Mastectomy, with immediate breast reconstruction
Description: It is an endoscopic approach for mastectomy using an axillary single port
Study: NCT05656352

Intervention type: DEVICE
Intervention: Masimo Total Hemoglobin SpHb® Continuous Non-invasive Hemoglobin Monitoring Device
Description: Masimo Radical-67® Pulse CO-Oximeter and rainbow® sensors.

Intervention type: DEVICE
Intervention: Masimo Total Hemoglobin SpHb® Continuous Non-invasive Hemoglobin Monitoring Device
Description: Masimo Radical-67® Pulse CO-Oximeter and rainbow® sensors.

Intervention type: DEVICE
Intervention: Masimo Total Hemoglobin SpHb® Continuous Non-invasive Hemoglobin Monitoring Device
Description: Masimo Radical-67® Pulse CO-Oximeter and rainbow® sensors.

Intervention type: DIAGNOSTIC_TEST
Intervention: Complete Blood Count
Description: The test will be done using venous blood collected in EDTA tubes. Samples will be analyzed within 6 hours of collection or stored at 2 to 8C and analyzed within 24 hours. Analysis will be done using a five-part differential hematology analyzer.

Intervention type: DIAGNOSTIC_TEST
Intervention: Complete Blood Count
Description: The test will be done using venous blood collected in EDTA tubes. Samples will be analyzed within 6 hours of collection or stored at 2 to 8C and analyzed within 24 hours. Analysis will be done using a five-part differential hematology analyzer.

Intervention type: DIAGNOSTIC_TEST
Intervention: Complete Blood Count
Description: The test will be done using venous blood collected in EDTA tubes. Samples will be analyzed within 6 hours of collection or stored at 2 to 8C and analyzed within 24 hours. Analysis will be done using a five-part differential hematology analyzer.
Study: NCT04505267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hafnium Oxide-containing Nanoparticles NBTXR3
Description: Given IT or intranodally

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT
Study: NCT06509958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR18034
Description: HR18034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR18034
Description: HR18034

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine Hydrochloride Injection
Description: Ropivacaine Hydrochloride Injection
Study: NCT04960241

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Homebased telerehabilitation
Description: The telerehabilitation intervention is based on sensor technology, developed by ICURA. The technology consists of motion sensors that can measure and analyse the quantity and quality of the exercises, and a mobile application that can guide the patients with visual response. A unique feature of ICURA trainer allows the physiotherapist to remotely supervise the individual patients exercise adherence and progress. The patients will receive a suitcase with five sensors (to be placed bilaterally on lower legs, thighs and one around the waist), a smartphone to record the exercises and a charging station free of charge during the 6-week intervention. At the end of the intervention the material will be returned at the first follow-up (t1). For more information please visit https://icura.dk.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Homebased rehabilitation
Description: The unsupervised rehabilitation group will receive a written exercise program in order to perform daily exercises at home. The exercise program will be made using Exorlive (for more information about Exorlive please visit https://www.exorlive.com). In addition to the written program, patients will able to use a link provided to see small video-instructions on the internet of each exercise on the program. No feedback or supplementary instructions will be given after the initial face-to-face appointment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No physical rehabilitation
Description: Patients allocated to the no intervention group will receive encouragement to stay active and be encouraged to gradually return to activities of daily living. This will be the only exercise-encouragement given to the no-intervention group.
Study: NCT05670925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus Famitinib with/without nab-Palitaxel
Description: After enrollment confirmed, the regimen of Camrelizumab Combined with Famitinib will be conducted for 2 cycles (8 weeks). Patients of CR or PR after 2 cycles (8 weeks) will enter dual-therapy maintenance phase until disease progression and will be recorded as PFS-1α. Patients of PD after 2 cycles (8 weeks) will be recorded as PFS-1β. Patients of SD with 2 cycles of dual therapy wlii receive triple therapy regimen: Camrelizumab and Famitinib with nab-Paclitaxel.
Study: NCT05539703

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Invitation to get a 2nd booster dose of COVID-19 vaccine
Description: Participants in the intervention group will receive an invitation to get a 2nd COVID-19 booster dose. Those who accept the invitation to be vaccinated will receive the vaccine through their municipality's vaccination service.
Study: NCT06023875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Cadonilimab 10mg/kg. The drug was administered every 3 weeks (Q3W), and 21 days (Q3W) was a treatment cycle. The treatment regimen is recommended for three cycles until the researchers determine that the subjects cannot continue to benefit, until the disease progression (PD), the toxicity cannot be tolerated, the treatment is delayed by more than 14 days, or the patient withdraws the informed consent form or dies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75mg/m2. Intravenous infusion was given every 3 weeks (Q3W), and 21 days (Q3W) was a treatment cycle. Treatment regimen is recommended for 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 60mg/m2. Intravenous infusion was given every 3 weeks (Q3W), and 21 days (Q3W) was a treatment cycle. Treatment regimen is recommended for 3 cycles.
Study: NCT05540314

Intervention type: PROCEDURE
Intervention: robotic bariatric surgery
Description: robotic bariatric surgery
Study: NCT05651178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human CD19-CD22 Targeted T Cells Injection
Description: Autologous genetically modified anti-CD19/CD22 CAR transduced T cells
Study: NCT04904822

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaginal bisection
Description: Uterine bisection vaginally by scalpel 24

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal bisection
Description: Uterine bisection by endokinfe
Study: NCT06582784

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Therapy App
Description: Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
Study: NCT05490264

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-NOTA-SNA002
Description: \[68Ga\]Ga-NOTA-SNA002（PD-L1 PET Tracer）for Positron Emission Tomography
Study: NCT06582784

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as Usual
Description: Participants will be provided educational material about mood management available via the EHR with the suggestion to discuss questions with their oncology provider. Participants will be asked to complete questionnaire measures weekly for 8 weeks with a final follow up at week 12.
Study: NCT05248321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid Powder
Description: 2g tranexamic acid powder will be given via the endoscopy directly to the peptic ulcer
Study: NCT05667766

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Release of Extended Pharmacogenomics Report at Week 1
Description: Whole genome sequencing with reporting on current standard of care (SoC) pharmacogenomic variants (TPMT, NUD15) where applicable (i.e, for patients with diagnosis of acute lymphoblastic leukaemia) by Week 1. Whole genome sequencing on a broader number of actionable variants as per international guidelines for cancer supportive care (identical to study arm) will be reported on at Week 13.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Release of Extended Pharmacogenomics Report at Week 13
Description: Whole genome sequencing with reporting on current standard of care (SoC) pharmacogenomic variants (TPMT, NUD15) where applicable (i.e, for patients with diagnosis of acute lymphoblastic leukaemia) and reporting of a broader number of actionable pharmacogenomic variants as per international guidelines for cancer supportive care reported on by Week 1.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Release of Extended Pharmacogenomics Report at Week 13
Description: Whole genome sequencing with reporting on current standard of care (SoC) pharmacogenomic variants (TPMT, NUD15) where applicable (i.e, for patients with diagnosis of acute lymphoblastic leukaemia) and reporting of a broader number of actionable pharmacogenomic variants as per international guidelines for cancer supportive care reported on by Week 1.
Study: NCT06446115

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Virtual Reality Headset applied to the participants during chemotherapy session. Participants select their preferred virtual reality experience (i.e., nature videos, meditations, interactive applications, etc). Virtual reality (VR) by definition, is a simulated experience consisting of an experiential environment created by hardware and software technology capable of provoking sensations of real experiences. It can be further divided into 1) immersive; 2) semi-immersive; and 3) non-immersive. Immersive VR employs head-mounted display (HMD) system technology to separate users from their surroundings and engage in real-time with a three-dimensional environment generated by a computer.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preferred activity
Description: Participants will engage in a preferred activity such as reading, watching television, coloring, etc. during chemotherapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Participants will be administered multiple pre and post intervention questionnaires including NCCN Distress thermometer, GAD-7 and CCVA.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Participants will be administered multiple pre and post intervention questionnaires including NCCN Distress thermometer, GAD-7 and CCVA.
Study: NCT05273190

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrotactile Stimulation
Description: Small electric motors, similar to a vibrating cell phone or gaming joystick, deliver vibration to the throat. Participants will assess cough symptoms throughout the study period.
Study: NCT06525805

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long Abstract
Description: The intervention and control group will be provided with a structured abstract of the review by Soderberg et al., entitled Percutaneous nephrolithotomy vs. retrograde intrarenal surgery for renal stones. This review was published once in the Cochrane Database of Systematic Reviews and once in the journal BJU International. The length of the abstract differs significantly depending on the journal.~The participants assigned to this study arm will be presented with the longer version published in the Cochrane Database, comprising 771 words (PMID: 37955353).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Short Abstract
Description: The participants assigned to this study arm will be presented with the shorter version published in BJU International, comprising 277 words (PMID: 37942649).
Study: NCT05327829

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: External non-invasive stimulation
Description: The participants are randomized into the block design of sham or tACS/tnVNS during the first three appointments or the last three appointments. Eye tracking will be used to test the predominant focus of decisions during the gaze phase on costs or difficulty levels during the COGED. The study is investigating the use of neuromodulation after TBI for improved cognitive function.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: COGED
Description: The COGED task consists of the classic N-back task of working memory-based decision making, followed by a valuation phase. The N-back phase of the task allows calculation of cognitive performance of a working memory task. During valuation, participants receive titrating offers of differing amounts of money to perform different difficulty levels of the N-back. The result is an effort discounting curve used to measure the individual effort cost. Effort discounting curves show the perceived cognitive effort required to complete each level of the task relative to another (typically the 1-back).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: COGED
Description: The COGED task consists of the classic N-back task of working memory-based decision making, followed by a valuation phase. The N-back phase of the task allows calculation of cognitive performance of a working memory task. During valuation, participants receive titrating offers of differing amounts of money to perform different difficulty levels of the N-back. The result is an effort discounting curve used to measure the individual effort cost. Effort discounting curves show the perceived cognitive effort required to complete each level of the task relative to another (typically the 1-back).
Study: NCT05284591

Intervention type: BIOLOGICAL
Intervention: Daratumumab
Description: intravenous or subcutaneous
Study: NCT06025123

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Early transnasal evaporative cooling with the RhinoChill device
Description: Early prehospital transnasal evaporative cooling followed by systemic hypothermia to 33 degrees Celsius for 24 hours and fever control for 72 hours
Study: NCT06506734

Intervention type: OTHER
Intervention: Questionnaires
Description: *  Psychosocial Impact of Dental Aesthetics Questionnaire  PMID 24280547~*  Orofacial Esthetic Scale  PMID 30856637~*  Orofacial Esthetic Scale  PMID 34231057~* A photograph of the patient's smile will be sent to 2 dentists who will also assess the presence or absence of dental dyschromia.
Study: NCT06106906

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T cell infusion
Description: CD19 CAR-T cell intravenous infusion
Study: NCT04846023

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: aEEG via vEEGix
Description: Amplitude-Integrated EEG can be achieved with a limited number of frontal electrodes. There is a new aEEG technology available: VEEGix, developed by NeuroServo Inc. It is a miniaturized aEEG, non-intrusive, portable and resistant to patient's movements. Its main advantage is its simplicity of use as a single adhesive strip including all electrodes is fixed to the patient's forehead and is connected to the VEEGix device
Study: NCT06540456

Intervention type: DRUG
Intervention: Qutenza® 8% Capsaicin Topical System
Description: Treatment of patients with neuropathic LBP and painful lumbosacral radiculopathy using the Qutenza 8% capsaicin topical system.
Study: NCT05822635

Intervention type: DEVICE
Intervention: SpyGlass Discover Digital System or SpyGlass DS Direct Visualization System
Description: Observational, prospective study for the clinical utility of the SpyGlass Discover Digital Catheter and the SpyScope DS Catheter during an intraoperative endoscopy procedure.
Study: NCT06161311

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DIMS lenses
Description: Defocus incorporated multiple segments lenses, which use induce peripheral myopic defocus to control for myopia development in children

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DIMS lenses
Description: Defocus incorporated multiple segments lenses, which use induce peripheral myopic defocus to control for myopia development in children
Study: NCT05558865

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: somnovia
Description: Participants receive access to the digital health application somnovia
Study: NCT01203670

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phytalgic
Description: Volunteers have to take three soft capsules per day, one in the morning and two in the evening.
Study: NCT06349148

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: enteral immunonutrition
Description: Patients in this group receives 2 bottles of immunonutrients per day (Impact, Nestlé, approximately 700 kcal).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: standard oral enteral nutrition
Description: Patients in the control group receives isoenergetic standard oral enteral nutrition ( emulsion or Nutrison).
Study: NCT05176470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lifileucel
Description: Given by IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study: NCT06084559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen therapy
Description: Mobile oxygen via pressurized bottle or mobile oxygen concentrator will be applied

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Oxygen therapy
Description: Patients will reveice pressurized air via a nasal cannula